Civica está desarrollando tres tipos de insulina genérica, conocida como biosimilar, que estarán disponibles tanto en viales como en plumas inyectables, a un costo de entre $30 y $55.
The debt ceiling crisis facing Washington puts Medicare and other popular entitlement programs squarely on the negotiating table this year as newly empowered Republicans demand spending cuts. Meanwhile, as more Americans than ever have health insurance, the nation’s health care workforce is straining under the load. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Tami Luhby of CNN, and Victoria Knight of Axios join KHN’s chief Washington correspondent Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts, or wherever you listen to podcasts. When the lame-duck Congress returns to Washington after Election Day, it will face a long list of health items needing attention before the end of the year, […]
Republicans would like to shift the political focus away from abortion to economic issues for the midterm elections, but a bill from Sen. Lindsey Graham (R-S.C.) that would ban most abortions after 15 weeks of pregnancy has put the issue squarely back on their agenda. The proposal was not welcomed by many of his colleagues, especially Minority Leader Mitch McConnell. Also this week, the muddle about where the fight against covid stands and near-record-low numbers of uninsured in the U.S. Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Margot Sanger-Katz of The New York Times join KHN’s partnerships editor, Mary Agnes Carey, to discuss these issues and more.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Congress is leaving for its annual summer break having accomplished far more than many expected, including, barring unforeseen snags, a bill to address the cost of prescription drugs for Medicare beneficiaries and extend the enhanced subsidies for insurance premiums under the Affordable Care Act. Meanwhile, the abortion issue continues to roil the nation as Indiana becomes the first state to ban the procedure in almost all cases since the Supreme Court overruled the constitutional right to abortion in June. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn’t result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
Republicans say Democrats are wrong to claim that birth control could be the Supreme Court’s next target. But Democrats have plenty of evidence that it might be.
As a Senate committee considered legislation to reauthorize the FDA’s user fee program, Sens. Bernie Sanders and Rand Paul agreed on a proposed amendment related to importing drugs from Canada, the U.K., and other nations.